News

Dr. Cheryl Marco offers unique insights into diabetes management through proper education and encouragement of insulin therapy and dietary changes.

Study co-chair Paul Ridker, MD, shares details behind the new global assessment of the IL-6 inhibitor for patients with atherosclerosis and CKD.

A multi-disciplinary approach could help better manage obesity following bariatric surgery.

An ophthalmologist provides insight into the harms of excessive blue light, and simple consumer resolutions.

New data shows that FT218 demonstrated clinically meaningful improvements regarding disrupted nighttime sleep compared to placebo in adults with narcolepsy.

The treatment represents the only FDA approved orally dissolving sublingual film for this patient population.

Significantly higher incidence rates of alopecia areata were seen in Hispanic children.

Barriers to sickle cell disease care are identified across multiple levels including individual, family, provider, and socio-environmental levels according to patient perspectives.

April 6 is Donate Life Living Donor Day, a day to promote liver donations.

The survey – the largest of its kind- found that 70% of people with trouble sleeping or insomnia reported being “desperate to find a solution”.

Patients with irritable bowel syndrome more frequently self-reported non-celiac gluten sensitivity compared to the control group, as well as major gastrointestinal symptoms found in the study included bloating, abdominal discomfort, and belching.

In recent years, researchers and advocates have vocalized increasing psychological support for patients with psoriasis.

The primary endpoint of improving near vision without compromising distance vision at Day 14, Hour 9 was met.

Dr. Karan Lal offers insights into diagnosing various forms of rosacea as well as common treatment methods.

Don't Miss a Beat hosts Drs. Vaduganathan and Greene provide insight into the results of trials from ACC.22 late-breaking sessions they highlighted in the preview episode they recorded ahead of the American College of Cardiology's 71st Annual Scientific Session.

In an interview, Karen Kozarsky, CSO of SwanBio discusses the new data being presented at AAN on AAV-based gene therapy candidate SBT101.

At the AAN 2022 Annual Meeting, SwanBio presents new data regarding lead candidate SBT101 for treating adrenomyeloneuropathy, a rare debilitating disease with no approved therapies.

National registry data suggest management and outcomes of ST-elevation myocardial infarction are returning to pre-pandemic levels, though vaccinated patients have fared better in mortality.

Data from PROMPT-HF show clinicians are more likely to add 1 of 4 topline drug classes to a patient's HFrEF regimen when alerted on the opportunity.

Data show omecamtiv mecarbil added to background therapy had no significant improvement regarding exercise capacity.

Mikhail Kosiborod, MD, discusses EMPULSE findings supporting hospital-stage treatment with the SGLT-2—regardless of patients' diabetes status.

Peter Sogaard discusses the benefit of monitoring for arrhythmias in patients with non-STEMI heart attacks and the need to look at arrhythmias in a different light.

Deepak Bhatt, MD, MPH, breaks down data from the SCORED trial presented at ACC.22, which demonstrated sotagliflozin provided significant benefit in terms of reducing total MACE, total MI, and total stroke, regardless of whether a patient had a history of cardiovascular disease.

Paul M. Ridker, MD, discusses the latest findings from the canakinumab trial before highlighting his team's work with ziltevekimab in ZEUS.

Dr. Butler discusses findings from the FIDELITY analyses on the consistent benefits of finerenone, regardless of ASCVD history in patients with CKD and T2D.

A discussion into broadening the findings of the SuperWIN trial and its potential effects on a larger, more at-risk population.

Dylan Steen, MD discusses positive findings from the trial on links between personalized education and DASH diet adherence.

Dupilumab is the only biologic medicine to show positive, clinically meaningful phase 3 results in adults and adolescents 12 years and older with EoE.